Recent News

04-09-24 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024

02-27-24 ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

02-16-24 ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

01-08-24 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023

11-13-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023

11-7-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023

10-5-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023

08-29-23 ImmuCell Announces Submission of CMC Technical Section to the FDA

08-10-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023

08-07-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023

07-11-23 ImmuCell Announces Preliminary, Unaudited Sales Results Q2 2023

06-28-23 ImmuCell Announces Change in Timing of Anticipated FDA Submission

06-21-23 ImmuCell Appoints Bryan K. Gathagan to Board of Directors

06-15-23 ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility

05-16-23 ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

05-11-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023

05-04-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023

04-05-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023

02-21-23 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022

02-15-23 ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022

01-09-23 ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022